1naresh2naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [4a97e1f8-bcca-4023-a30a-ac3000b8d8b4] => Array ( [runtime-id] => 4a97e1f8-bcca-4023-a30a-ac3000b8d8b4 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [054e135f-6fc7-48de-82ae-b693d98fa77b] => Array ( [runtime-id] => 054e135f-6fc7-48de-82ae-b693d98fa77b [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;6a208f4d2530df8f82afd9df71204c0bdb35538e ) ) ) 1naresh2nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [4a97e1f8-bcca-4023-a30a-ac3000b8d8b4] => Array ( [runtime-id] => 4a97e1f8-bcca-4023-a30a-ac3000b8d8b4 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [054e135f-6fc7-48de-82ae-b693d98fa77b] => Array ( [runtime-id] => 054e135f-6fc7-48de-82ae-b693d98fa77b [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;6a208f4d2530df8f82afd9df71204c0bdb35538e ) ) )Summary of results from the control and 3 study groups
Group Control Group: Non-SIH Study Group 1: SIH+/CSF Leak−/ Hyperdense Vein− Study Group 2: SIH+/CSF Leak+ Study Group 3: SIH+/ Hyperdense Vein+ Included patients (No.) 47 83 44 17 Mean age (range) (yr) 66 (35–91) 59 (31–87) 54 (28–71) 56 (37–84) Male sex 62% 45% 36% 41% Mean intrathecal contrast volume injected (range) (mL) 14 (10–20) 15 (12–20) 13 (6–20) 14 (12–18) Initial CTM All patients: mean time from contrast injection to initial CTM (range) (min) 35 (19–101) 40 (2–113) 20 (2–87) 41 (4–83) Patients with renal contrast (No.) (%) 0/47 (0%) 10/83 (12%) 1/44 (2%) 7/17 (41%) Patients with renal contrast: mean time from contrast injection to initial CTM (range) (min) NA 61 (17–96) Contrast injection time not documented in this patient 37 (4–62) Delayed imaging Patients with delayed imaging (No.) (%) 0/47 (0%) 73/83 (88%) 11/44 (25%) 15/17 (88%) All patients: mean time from contrast injection to delayed CTM (range) (min) NA 199 (79–364) 162 (93–325) 195 (100–386) Patients with renal contrast (No.) (%) NA 23/73 (32%) 3/11 (27%) 8/15 (53%) Patients with renal contrast: mean time from contrast injection to delayed imaging (range) (min) NA 220 (126–364) 211 (97–325) 184 (100–386)
Note:—NA indicates not applicable.